Haemonetics
Blood-collection platforms and hospital devices for transfusion, surgery, and cardiac procedures.
Something off on this page? Send us feedback.
Profile
Sells automated apheresis systems, single-use disposables, donor software, hospital blood-management tools, and interventional devices. Revenue spans Apheresis and MedSurg; plasma collections pair equipment, disposables, and software, while sales remain concentrated among several large operators.
Supplies automated collection systems, single-use disposables, donor-management software, and services through Apheresis, serving plasma centers and blood collectors worldwide. NexSys PCS and its Persona technology tailor source-plasma collections, while MCS and related systems collect and process blood components. The platform links devices with center workflows and software, supporting yield, donor safety, and operating efficiency.
MedSurg combines Blood Management Technologies—TEG hemostasis testing, Cell Saver surgical blood recovery, and SafeTrace Tx and BloodTrack transfusion software—with Interventional Technologies such as VASCADE vascular closure, SavvyWire and OptoWire sensor-guided devices, and ensoETM esophageal cooling. Device approvals vary by country, most consumables are manufactured internally, and Plasma sales remain concentrated among several large collection operators.
Company facts
Key statistics
Year to date +29.9% · Average volume (30d) 795.6K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | Robert W. Baird | Target | $96 | $119 | ||
| Aug 19, 2026 | Barrington | Target | $95 | $118 | ||
| Aug 7, 2026 | Raymond James | Reiterate | Outperform | $90 | $105 | |
| Aug 7, 2026 | Robert W. Baird | Target | $67 | $96 | ||
| Aug 7, 2026 | Barrington | Target | $89 | $95 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q1 FY27 | $1.08 | $1.14 | +5.6% | $327.9M | $339.4M | +3.5% | +1.70% |
| May 7, 2026Q4 FY26 | $1.28 | $1.29 | +0.8% | $336.8M | $346.4M | +2.8% | +1.38% |
| Feb 5, 2026Q3 FY26 | $1.27 | $1.31 | +3.1% | $331.9M | $339.0M | +2.1% | −8.74% |
| Nov 6, 2025Q2 FY26 | $1.12 | $1.27 | +13.4% | $329.8M | $327.3M | −0.7% | +1.86% |
Financial highlights
| 12 quarters | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|
| Revenue | $330.6M | $321.4M | $327.3M | $339.0M | $346.4M | $339.4M | |
| Gross profit | $181.9M | $191.9M | $183.4M | $191.4M | $198.2M | $202.8M | |
| Operating income | $51.5M | $53.9M | $67.3M | $69.6M | $51.4M | $57.5M | |
| Net income | $58.0M | $34.0M | $38.7M | $44.7M | −$20.1M | $33.0M | |
| Diluted EPS | $1.17 | $0.70 | $0.81 | $0.95 | −$0.44 | $0.72 | |
| Gross margin | 55.0% | 59.7% | 56.0% | 56.5% | 57.2% | 59.8% | |
| Operating margin | 15.6% | 16.8% | 20.6% | 20.5% | 14.9% | 16.9% |
Fiscal years (4-quarter sums)FY22 $993.2M · FY23 $1.17B · FY24 $1.31B · FY25 $1.36B · FY26 $1.33B
Revenue by product · Q1 FY27
Revenue by geography · Q1 FY27
Balance sheet, Jun 27, 2026Cash & short-term investments $223.4M · Total debt $1.17B · Total assets $2.37B · Shareholders' equity $837.1M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 45.45M · Float 44.84M · 98.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.91M | 13.00% | 13F | Aug 7, 2026 |
| Neuberger Berman Group LLC | 4.18M | 9.20% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 2.55M | 5.60% | 13F | Aug 13, 2026 |
| AQR Capital Management LLC | 2.27M | 4.99% | 13F | Aug 14, 2026 |
| Ariel Investments, LLC | 2.06M | 4.53% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 10, 2025 | Mark W. Kroll | director | +1,400 | $70.56 |
Peers
- Abbott
Dominant vascular closure and wireless coronary physiology platform
- LivaNova
Global cardiac surgery platform combining HLM, oxygenators, and cell salvage
- Boston Scientific
Major cardiovascular medtech with FFR wires, PFA ablation, and IVUS imaging
- Philips (ADR)
Coronary physiology leader via iFR platform, OmniWire, and IGT imaging systems
- Medtronic
Global medtech leader; competes in cell salvage via active autoLog IQ system
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Haemonetics | $103.80 | −0.09% | $4.72B | 51.0 | 18.9 | 3.5 | +5.6% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| LivaNova | $80.32 | −0.02% | $4.41B | 23.7 | 18.2 | 3.0 | +10.8% |
| Boston Scientific | $46.85 | +0.03% | $69.62B | 19.0 | 14.2 | 3.3 | +7.5% |
| Philips (ADR) | $26.72 | +0.06% | $26.12B | 19.9 | 13.7 | 1.3 | −2.9% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Median | 23.7 | 15.3 | 3.2 | +9.9% |